U.S. Opioid and Non-Opioid Pain Management Pharmaceuticals Markets
- Language: English
- 87 Pages
- Published: February 2007
- Region: North America
BACKGROUND AND PROJECT OVERVIEW
Hundreds of millions of Americans suffer from chronic pain, significantly reducing their quality of life. With this, opioid therapy is becoming more common, leading to increases in concern on issues of abuse and misuse. Additionally, the FDA recently released a statement notifying sponsors and manufacturers of long-acting and extended-release (LA/ER) opioids of the need to develop Risk Evaluation and Mitigation Strategies (REMS) programs in order to ensure the benefits of this therapy choice outweigh any potential risks. There is little research on the current processes physicians use when deciding when and how to counsel patients on the risks and safe use of opioid therapy, nor are there detailed studies on physician opinions of opioid-prescribing and education regulations. This paper presents initial data on the factors involved in the decision-making process of initiating a conversation about the risks and safe use of LA/ER opioids. Additionally, information is gathered on the attitudes surrounding new opioids regulations, including familiarity with the FDA-proposed REMS requirements.
STUDY OBJECTIVES
Based on the identified gaps
READ MORE >
1. CONTEXT AND OBJECTIVES
2. DESIGN AND METHODS
3. SAMPLE DEMOGRAPHICS AND DESCRIPTIVE DATA
Discussing opioid risks and safe use with patients
Familiarity with and attitudes toward opioid regulations
Educational barriers to opioid prescription
4. FACTORS PREDICTING INITIATING A DISCUSSION REGARDING THE RISKS AND SAFE USE OF LA/ER OPIOID THERAPY
5. CONCLUSIONS AND IMPLICATIONS
APPENDIX A: SURVEY INSTRUMENT
APPENDIX B: COMPLETE DATA TABLES
APPENDIX C: REFERENCES
After a thorough literature review was conducted to ascertain the current attitudes and practice of physicians regarding opioid therapies, a survey was designed and distributed to primary care physicians (PCPs) through an online link in October 2011. Data collected from 201 PCPs were compiled for descriptive analysis and then analyzed to determine differences by various demographic groups. A logistic regression was run to determine the main predictors of initiating a discussion regarding the risks and safe use of long-acting or extended-release opioid therapy.
| Format | Properties | |
|---|---|---|
| Enterprisewide | The report will be emailed to you. The report is sent in PDF format. | This is an enterprise license, allowing all employees within your organisation access to the product. |
| Hard Copy | A printed copy of the report will be shipped to you. |